Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis

Table 3

Update (June 2009) of results on 24 patients treated with mDC vaccine.

Patient ID	𝑛vaccinations	DTH Best response   after 4 or more vaccinations		Vitiligo	Clinical response	Response duration	OS (Months)
		ATL	KLH
(1) P.M	7	−	−		PR	3	14
(2) P.M	15	++	++++		MR	6	22
(3) R.L.	10	−	++		SD	9	14
(4) G.D.	16	++	+++	+	CR	8	34
(5) R.G.	4	−	+++		PD	—	8
(6) T.A.	13	−	++		MR	12	41
(7) B.A.	4	−	−		PD	—	7
(8) C.P.	6	−	++		PD	—	20
(9) O.M.	4	−	−		PD	—	5
(10) LB.	4	−	−		PD	—	3
(11) M.J.	8+8+8+4	+	+++	+	CR	15+^∗	52+
(12) O.G.	5	−	−		PD	—	3
(13) M.R.	4	+	++		PD	—	6
(14) DiI.G	10	+	+		CR	36+	39+
(15) B.F	21	++	++		PR	20+^∗	40+
(16) I.I	6	−	−		PD	—	7
(17) B.I	4	++	−/+	+	PR	21+^∗	31+
(18) S.L	9	−	+		SD	7	22
(19) N.F.	6	++	+		PR	5	8
(20) B.R	12	+++	+++		SD	8	10
(21) S.M	11	−	−		PD	—	12
(22) M.C	6	−	+		PD	—	61+
(23) R.G	5	−	−		PD	—	60+
(24) B.R	13	+	+++		SD	11	16

PR: partial response; MR: mixed response; SD: stable disease; CR: complete response; PD: progressive disease; OS: overall survival; DTH: delayed-type hypersensitivity test; ^∗responses obtained with palliative surgery+vaccine alternating; Grey area, 11 patients given postvaccine therapy.